Last reviewed · How we verify
NCT01091714
Is Omega-3 Fatty Acid RBC Saturation Product Dependent?
Phase 4 trial testing Omega-3 in Cardioprotective Levels in 60 participants. Completed in 1 July 2011.
1 July 2011
Quick facts
| Lead sponsor | Bucci Laser Vision Institute |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 60 |
| Start date | 1 October 2010 |
| Primary completion | 1 July 2011 |
| Estimated completion | 1 July 2011 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Omega-3
- Omega-3
- Omega-3
Conditions studied
- Cardioprotective Levels — all drugs for Cardioprotective Levels →
Sponsor
Bucci Laser Vision Institute
Who can join
18 and older, any sex, with Cardioprotective Levels. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
RBC saturation of Omega-3 fatty acids reaching cardioprotective levels as proven with HS-Omega_3 Index test.
Time frame: one month
Sponsor's own description
To demonstrate that RBC saturation of the Omega-3 fatty acids reaching cardioprotective levels as proven with the HS-Omega-3 Index test will be achieved most efficiently depending on a specific product utilized within this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01091714
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Omega-3
Trials testing the same drug.
- NCT07136519 — Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma · Phase 2 · not yet recruiting
- NCT06538324 — Response to an Intervention With Omega-3 (RIO - Study) · NA · completed
- NCT05990712 — The Effect of a Pre-cataract Surgical Ocular Hygiene Regime on Microbial Load, Tear Osmolarity, Dry Eye, and Inflammator · Phase 4 · unknown
- NCT05711810 — Medicine-induced Cardiac Hemodialysis on COVID-19 · Phase 4 · completed
- NCT07365553 — Omega-3, Autism Spectrum Disorder (ASD) · NA · recruiting
Other Bucci Laser Vision Institute trials
Trials by the same sponsor.
- NCT06016231 — Clinical Outcomes of Patients with a Light Adjustable Lens (LAL) in At Least One Eye · completed
- NCT05610540 — Patient Preference and Visual Quality With Contralateral Synergy Versus Panoptix · completed
- NCT04120987 — Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra · Phase 4 · withdrawn
- NCT04134507 — Patient Satisfaction in Post-LASIK Patients With Presbyopia-Correcting IOLs vs. Post-Lasik Patients With Monofocal IOLs · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01091714 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bucci Laser Vision Institute
- Last refreshed: 4 October 2011
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01091714.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing